Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

MRI may help tailor breast cancer chemo early

NCT ID NCT00462696

Knowledge-focused Sponsor: Institut Bergonié Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether MRI scans can detect how well breast cancer responds to chemotherapy early in treatment. Sixteen women with invasive breast cancer received standard chemo before surgery, and their MRI results were checked by two radiologists. The goal was to see if MRI measurements are reliable enough to guide treatment decisions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
epirubicin and docetaxel (chemotherapy)
What this could lead to
If MRI proves reliable, it could help doctors adjust chemotherapy early for better outcomes.
What could go wrong
This is a very small, early study (16 people) focused on imaging reproducibility, not on treatment success or survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

16 people

The number who actually took part.

Started

Feb 2006

Finished

Dec 2008

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

DISEASE CHARACTERISTICS: * Histologically confirmed infiltrative breast cancer meeting 1 of the following criteria: * Operable T2 or T3, M0 disease * Locally advanced disease (T4a, b, or c) * No T4d disease * Indication for neoadjuvant chemotherapy before breast-conserving surgery * No desire by patient for complete mastectomy * No overexpression of HER-2 * No multifocal tumor * Hormone receptor status not specified PATIENT CHARACTERISTICS: * Female * Menopausal status not specified * Life expectancy \> 6 months * No contraindication to MRI with contrast, including any of the following: * Claustrophobia * Prior major allergies * Cardiac pacemaker * Surgical clips * Certain cardiac valves * Sunken or hollow filters * Implanted pump * Cochlear implants * Metallic foreign body (intra-ocular) * No contraindication to chemotherapy or surgery * No other serious condition that would preclude study therapy * No other uncontrolled medical condition, including any of the following: * Thyroid disease * Neuropsychiatric disease * Infection * Insufficient coronary capacity * NYHA class III-IV heart disease * No HIV positivity * Not pregnant or nursing PRIOR CONCURRENT THERAPY: * See Disease Characteristics * No prior chemotherapy, radiotherapy, or surgery for ipsilateral breast cancer * No prior biopsy of tumor before MRI * No MRI at another center within the past 15 days * No participation in another investigational study of anticancer therapy within the past 30 days

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm invasive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer

Contacts and locations

Locations

  • Institut Bergonie

    Bordeaux, 33076, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.